Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Expenses (2023 - 2025)

NewAmsterdam Pharma's Operating Expenses history spans 3 years, with the latest figure at $66.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 17.88% year-over-year to $66.0 million; the TTM value through Dec 2025 reached $248.2 million, up 11.87%, while the annual FY2025 figure was $248.2 million, 11.87% up from the prior year.
  • Operating Expenses for Q4 2025 was $66.0 million at NewAmsterdam Pharma, up from $55.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $71.9 million in Q1 2025 and bottomed at $44.2 million in Q2 2023.
  • The 3-year median for Operating Expenses is $54.8 million (2024), against an average of $55.6 million.
  • The largest YoY upside for Operating Expenses was 26.41% in 2025 against a maximum downside of 0.13% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $51.9 million in 2023, then increased by 7.95% to $56.0 million in 2024, then increased by 17.88% to $66.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Operating Expenses are $66.0 million (Q4 2025), $55.5 million (Q3 2025), and $54.8 million (Q2 2025).